|
Fernandez S, Moreno-Castano AB, Palomo M, Martinez-Sanchez J, Torramade-Moix S, Tellez A, Ventosa H, Segui F, Escolar G, Carreras E, Nicolas JM, Richardson E, Garcia-Bernal D, Carlo-Stella C, Moraleda JM, Richardson PG, Diaz-Ricart M, Castro P. Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. Shock. 2022 Jan 1;57(1):95-105. doi: 10.1097/SHK.0000000000001823. PubMed PMID: 34172614; PubMed Central PMCID: PMC8662948.
AÑO: 2022; IF: 3.1
|
34172614
|
Garcia-Bernal D, Richardson E, Vlodavsky I, Carlo-Stella C, Iacobelli M, Jara R, Richardson PG, Moraleda JM. Endothelial dysfunction and its critical role in COVID-19-associated coagulopathy: Defibrotide as an endothelium-protective, targeted therapy. EJHaem. 2021 Jun 22;2(3):680-681. doi: 10.1002/jha2.198. eCollection 2021 Aug. No abstract available. PubMed PMID: 34518829; PubMed Central PMCID: PMC8426874.
AÑO: 2021
|
|
Ruiz-Lafuente N, Minguela A, Moraleda JM, Muro M, Parrado A. Variable Distribution of DOCK-D Proteins between Cytosol and Nucleoplasm in Cell Lines, Effect of Interleukin-4 on DOCK10 in B-Cell Lymphoid Neoplasms, and Validation of a New DOCK10 Antiserum for Immunofluorescence Studies. Antibodies (Basel). 2021 Aug 20;10(3):33. doi: 10.3390/antib10030033. PubMed PMID: 34449554; PubMed Central PMCID: PMC8395434.
AÑO: 2021
|
|
Soria-Juan B, Garcia-Arranz M, Llanos Jimenez L, Aparicio C, Gonzalez A, Mahillo Fernandez I, Riera Del Moral L, Grochowicz L, Andreu EJ, Marin P, Castellanos G, Moraleda JM, Garcia-Hernandez AM, Lozano FS, Sanchez-Guijo F, Villaron EM, Parra ML, Yanez RM, de la Cuesta Diaz A, Tejedo JR, Bedoya FJ, Martin F, Miralles M, Del Rio Sola L, Fernandez-Santos ME, Ligero JM, Morant F, Hernandez-Blasco L, Andreu E, Hmadcha A, Garcia-Olmo D, Soria B. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial). Trials. 2021 Sep 6;22(1):595. doi: 10.1186/s13063-021-05430-2. PubMed PMID: 34488845; PubMed Central PMCID: PMC8420067.
AÑO: 2021; IF: 2.728
|
|
Molina ML, Garcia-Bernal D, Salinas MD, Rubio G, Aparicio P, Moraleda JM, Martinez S, Valdor R. Chaperone-Mediated Autophagy Ablation in Pericytes Reveals New Glioblastoma Prognostic Markers and Efficient Treatment Against Tumor Progression. Front Cell Dev Biol. 2022 Mar 18;10:797945. doi: 10.3389/fcell.2022.797945. eCollection 2022. PubMed PMID: 35419364; PubMed Central PMCID: PMC8997287.
AÑO: 2022; IF: 5.5
|